Shiloah 1000
Alternative Names: S-1K; Shiloah-1000; Siloah-1000Latest Information Update: 26 Sep 2024
At a glance
- Originator Ensol Biosciences
- Class Antihyperglycaemics; Peptides
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 1 diabetes mellitus
Most Recent Events
- 25 Sep 2024 Phase-I clinical trials in Type 1 diabetes mellitus (PO) prior to September 2024 (Ensol Biosciences pipeline, September 2024)
- 28 Jun 2024 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in South Korea (PO)
- 26 May 2020 Preclinical trials in Type 1 diabetes mellitus in South Korea (PO) (Ensol Biosciences pipeline, May 2020)